28-Aug-2026
Celcuity Files sNDA to Expand REVTORPYK Breast Cancer Use
TipRanks (Wed, 26-Aug 8:57 AM ET)
Globe Newswire (Wed, 26-Aug 8:30 AM ET)
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Aug 4:06 PM ET)
PRNewswire (Thu, 6-Aug 11:02 PM ET)
Globe Newswire (Tue, 4-Aug 5:43 PM ET)
Business Wire (Mon, 3-Aug 8:19 PM ET)
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Business Wire (Sun, 2-Aug 5:27 PM ET)
PRNewswire (Fri, 31-Jul 11:22 AM ET)
PRNewswire (Thu, 30-Jul 10:01 AM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of August 28, 2026, CELC stock price declined to $88.44 with 498,306 million shares trading.
CELC has a beta of 2.24, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.16 to the broad based SPY ETF.
CELC has a market cap of $4.33 billion. This is considered a Mid Cap stock.
Last quarter Celcuity reported $0 in Revenue and -$1.07 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.01.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CELC has outperformed the market in the last year with a return of +62.0%, while the SPY ETF gained +19.7%. However, in the most recent history, CELC shares have underperformed the stock market with its stock returning -32.4% in the last 3 month period and -3.9% for the last 2 week period, while SPY has returned +2.2% and -0.9%, respectively.
CELC support price is $90.52 and resistance is $95.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.
